Article type: Short Communication

Authors: Yilmaz, Alia; * | Geddes, Tima | Han, BeomSoob | Bahado-Singh, Ray O.a | Wilson, George D.a | Imam, Khaleda | Maddens, Michaela | Graham, Stewart F.c

Affiliations: [a] Beaumont Research Institute, Beaumont Health, Royal Oak, MI, USA | [b] Departments of Biological and Computing Sciences, University of Alberta, Edmonton, AB, Canada | [c] Oakland University-William Beaumont School of Medicine, Beaumont Health, Royal Oak, MI, USA

Correspondence: [*] Correspondence to: Ali Yilmaz, Beaumont Research Institute, Beaumont Health, 3811W. 13 Mile Road, Royal Oak, MI 48073, USA. Tel.: +1 248 551 2377; E-mail: [email protected].

Abstract: Using 1H NMR metabolomics, we biochemically profiled saliva samples collected from healthy-controls (n = 12), mild cognitive impairment (MCI) sufferers (n = 8), and Alzheimer’s disease (AD) patients (n = 9). We accurately identified significant concentration changes in 22 metabolites in the saliva of MCI and AD patients compared to controls. This pilot study demonstrates the potential for using metabolomics and saliva for the early diagnosis of AD. Given the ease and convenience of collecting saliva, the development of accurate and sensitive salivary biomarkers would be ideal for screening those at greatest risk of developing AD.

Keywords: Alzheimer’s disease, 1H NMR, metabolomics, mild cognitive impairment

DOI: 10.3233/JAD-161226

Journal: Journal of Alzheimer's Disease, vol. 58, no. 2, pp. 355-359, 2017